Genprex, Inc. GNPX

GNPX Company Overview

Genprex, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for cancer and diabetes. The company operates within the biotechnology and biopharmaceutical industries, with its primary emphasis on oncology and metabolic disease therapeutics. Genprex’s core strategy centers on utilizing non-viral gene delivery technologies designed to introduce tumor suppressor genes or therapeutic genes into targeted cells. Its principal revenue model remains development-stage oriented, as the company has not yet commercialized approved products and primarily relies on capital markets financing, research activities, and strategic collaborations.

The company’s lead oncology program is Reqorsa Gene Therapy, formerly known as Oncoprex, which is being evaluated primarily for non-small cell lung cancer and other solid tumors. Genprex is also advancing diabetes-focused programs, including gene therapy candidates intended to address Type 1 and Type 2 diabetes through pancreatic cell reprogramming technologies licensed from academic institutions. The company was founded in 2009 and is headquartered in Austin, Texas. Over time, Genprex evolved from an early-stage oncology gene therapy developer into a broader genetic medicines company with multiple therapeutic platforms targeting high unmet medical needs.